Past and present
2 weeks ago
***PKTX..
Stem Cell Therapy Reverses Diabetes..***
According to a new study published in Science Advances, researchers have developed a novel cell transplantation technique that successfully reversed type 1 diabetes in mice, using human islets vascularized with adaptable endothelial cells for functional subcutaneous engraftment.
Breakthrough in Islet Transplantation
The innovative technique employs human reprogrammed vascular endothelial cells (R-VECs) to functionally vascularize pancreatic islets, addressing a major challenge in islet transplantation therapy1. This approach enables:
In vitro functional vascularization of islets with responsive glucose-stimulated insulin secretion
Successful reversal of hyperglycemia in diabetic mice through subcutaneous transplantation
High levels of human insulin in recipient serum, with hyperglycemia returning upon graft removal
R-VECs, engineered by transiently expressing the vascular-specific transcription factor ETV2, demonstrate remarkable adaptability by self-assembling into perfusable vascular networks and acquiring islet endothelial cell-specific characteristics when cocultured with human islets12. This breakthrough represents a significant step towards improved islet transplantation therapy, potentially offering a path to long-term insulin independence for type 1 diabetes patients34.
ncbi.nlm.nih.gov favicon
science.org favicon
pubmed.ncbi.nlm.nih.gov favicon
4 sources
Role of R-VECs in Vascularization
Microenvironmental determinants of endothelial cell ...
Reprogrammed vascular endothelial cells (R-VECs) play a crucial role in enhancing islet transplantation outcomes by providing robust vascularization. Their unique properties and adaptability make them particularly effective for supporting islet survival and function:
R-VECs form extensive vascular networks that arborize and penetrate islets, mimicking native pancreatic vasculature12
When co-cultured with islets, R-VECs acquire islet endothelial cell-specific characteristics, demonstrating remarkable adaptability34
R-VEC-formed blood vessels have larger diameters (13.5 Β± 7.5 Β΅m) compared to native human islet capillaries (6.8 Β± 2.1 Β΅m), potentially improving blood flow1
Cotransplanted R-VECs contribute substantially more to islet vascularization than host endothelial cells in subcutaneous transplants1
The vascular network formed by R-VECs successfully anastomoses with host circulation, ensuring long-term graft survival31
This advanced vascularization technique addresses a major challenge in islet transplantation, potentially improving graft survival and function while enabling transplantation in more accessible sites like the subcutaneous space.
pubmed.ncbi.nlm.nih.gov favicon
ncbi.nlm.nih.gov favicon
4 sources
Subcutaneous Transplantation Success
Subcutaneous transplantation of vascularized islets marks a significant advancement in type 1 diabetes treatment. This site offers several advantages, including a large surface area, easy accessibility for transplantation and monitoring, and potential graft retrieval if necessary1. Previous attempts at subcutaneous islet transplantation had failed due to insufficient vascularization, but the use of R-VECs overcomes this challenge by forming blood vessels that arborize and vascularize the islets, effectively connecting with the host circulation23.
Transplanted R-VECs form functional blood vessels that support islet survival
Subcutaneous site allows for non-invasive monitoring and potential graft removal
Successful reversal of hyperglycemia in diabetic mice demonstrates the technique's efficacy12
ncbi.nlm.nih.gov favicon
science.org favicon
3 sources
Implications for Type 1 Diabetes
This innovative approach addresses several key challenges in islet transplantation therapy, including the scarcity of donor organs and islet loss due to disconnection from extracellular matrix and vasculature during isolation1. By enabling effective vascularization, the technique potentially reduces inflammatory and rejection reactions that compromise islet survival1. Importantly, this method may pave the way for transplantation without the need for lifelong immunosuppression, a significant drawback of conventional approaches2. The success of this technique in animal models represents a promising step towards translating this therapy to human patients, offering hope for a more effective and durable treatment for type 1 diabetes34.
HyperPirate75
1 month ago
Interesting opinion but i think you are wrong, this stock has been manipulated and accumulated for years, if they do end up posting positive data for a study about diabetes 1, the stock will go up. Islet transplant is a very new method to treat diabete 1 and Alberta uni is at the forefront of this new method, if PKTX enables safer and more efficient islet transplant, it will be a big deal